Enclomiphene Citrate Cost in South Dakota 2026

What Does Enclomiphene Citrate Actually Cost in South Dakota?

Most South Dakota men pay roughly $90 per month for compounded enclomiphene citrate in 2026. That figure covers a 30-day supply of oral capsules at the standard starting dose of 12.5 to 25 mg daily dispensed by a state-licensed or nationally operating 503A compounding pharmacy. No FDA-approved branded oral enclomiphene product (such as Androxal, which completed Phase III trials but was never commercially launched in the U.S.) is available at South Dakota retail chains, so cash-pay compounding is the default pathway for essentially every patient in the state.

The $90 monthly estimate is consistent with prices reported across comparable Midwest states. Patients who require dose escalation to 25 mg daily may see prices inch toward $100, $110 per month depending on the compounder, but the increase is rarely dramatic because the active ingredient volume is small. Shipping costs from out-of-state 503A pharmacies, which serve the majority of South Dakota patients given the state's limited local compounding infrastructure, typically add $0, $15 per order and are sometimes waived on auto-refill subscriptions.

For context, clomiphene citrate (the racemic parent compound from which enclomiphene is derived) remains generically available at roughly $30, $50 per month at South Dakota retail pharmacies. Some providers still prescribe low-dose clomiphene off-label for male hypogonadism when cost is the primary concern, though Kim et al. (BJU Int, 2016, N=180) demonstrated that enclomiphene produces statistically superior testosterone restoration with fewer estrogenic side effects compared with clomiphene in men with secondary hypogonadism [1]. That pharmacodynamic difference justifies the price premium for most patients.

The FDA's review of enclomiphene's clinical data is documented on the agency's drug-approval portal [2], and the full trial package supporting its testosterone-raising efficacy in men with documented low T (morning total testosterone <300 ng/dL on two measurements) has been publicly accessible since the NDA submissions [3].

Why There Is No Branded Retail Price to Compare

Enclomiphene has no commercially available branded oral product on U.S. pharmacy shelves as of 2026. This is a significant practical point that separates its pricing from drugs like semaglutide or testosterone cypionate.

Repros Therapeutics submitted Androxal (trans-enclomiphene citrate) for FDA approval and received a Complete Response Letter in 2013 citing the need for additional cardiovascular safety data [4]. The company subsequently dissolved, and no other sponsor has achieved a successful NDA for oral enclomiphene. Because there is no approved product, there is no manufacturer list price, no WAC (wholesale acquisition cost), and no branded co-pay assistance card. Every patient in South Dakota is therefore using the drug under the 503A compounding framework.

This also means that standard retail drug-pricing databases (GoodRx, RxSaver, NeedyMeds) display either no price or a price for clomiphene, not enclomiphene. Patients who search those platforms and see a low price are almost always viewing the racemic clomiphene generic, not the enclomiphene trans-isomer. Providers should clarify this distinction during the prescribing visit to prevent dispensing errors.

A 2023 systematic review in the Journal of Urology confirmed that both enantiomers of clomiphene stimulate LH and FSH release via hypothalamic estrogen-receptor antagonism, but that the zuclomiphene (cis) isomer accumulates in tissue and is associated with estrogenic adverse effects [5]. Enclomiphene isolates the trans-isomer to remove that accumulation liability.

South Dakota Medicaid Coverage for Enclomiphene Citrate

South Dakota Medicaid does not cover enclomiphene citrate. The drug is used off-label for secondary hypogonadism in men, a condition for which South Dakota Medicaid's preferred drug list does not include any selective estrogen receptor modulator (SERM). Prior authorization requests for enclomiphene are routinely denied on two grounds: the absence of an FDA-approved indication and the off-label classification.

The South Dakota Department of Social Services administers Medicaid benefits for approximately 135,000 enrollees as of 2024 [6]. The pharmacy benefit follows a closed formulary model for most non-emergency outpatient drugs. Testosterone replacement therapies such as testosterone cypionate injectable (a covered generic) and some topical testosterone gels are on the formulary for diagnosed hypogonadism, but SERMs used to stimulate endogenous testosterone production are not recognized as a covered category.

Patients on Medicaid who want enclomiphene should expect full out-of-pocket costs. At $90/month, the annual burden is approximately $1,080. Some telehealth platforms offer sliding-scale consultation fees for patients who can demonstrate financial hardship, which partially offsets the medication cost even when the drug itself carries no subsidy.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that SERMs represent a reasonable pharmacologic option for men with secondary hypogonadism who wish to preserve fertility, a consideration that pure testosterone replacement does not address [7]. That guideline framing has not translated into Medicaid formulary inclusion in South Dakota as of the 2026 plan year.

Is Compounded Enclomiphene Citrate Legal in South Dakota?

Yes. Compounded enclomiphene citrate is legal in South Dakota when dispensed by a 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The 503A framework, established under Section 503A of the Federal Food, Drug, and Cosmetic Act, permits state-licensed pharmacies to compound drugs that are not commercially available as an FDA-approved product, provided specific conditions are met [8].

Enclomiphene citrate is not on the FDA's 503A Bulks List of prohibited compounding substances as of 2025, which means 503A pharmacies may legally compound it. The key conditions are:

A licensed prescriber (MD, DO, NP, or PA with prescribing authority) must write a patient-specific prescription. The compounding pharmacy must be licensed in its home state and, if shipping across state lines, must comply with the destination state's pharmacy board requirements. South Dakota Board of Pharmacy regulations allow receipt of compounded medications from out-of-state 503A pharmacies as long as the dispensing pharmacy holds the appropriate non-resident pharmacy license. South Dakota does not impose additional SERM-specific restrictions beyond standard controlled-substance and non-controlled compound rules.

One practical nuance: enclomiphene is not a controlled substance under DEA schedules, which simplifies prescribing. A telehealth provider can issue a valid prescription without a DEA number specifically tied to Schedule III (as would be required for testosterone). This reduces prescribing friction substantially.

The FDA's 503A regulatory framework page provides the current compounding authority boundaries [8], and providers should verify the pharmacy's NABP accreditation before routing patients to any specific compounder.

How Insurance Works (and Usually Does Not Work) for Enclomiphene in South Dakota

Commercial insurance coverage for enclomiphene citrate in South Dakota is extremely rare. Because there is no FDA-approved product, insurers cannot process a standard pharmacy claim tied to an NDC code. Compounded drugs generally lack NDCs, and most pharmacy benefit managers (PBMs) such as Express Scripts, OptumRx, and CVS Caremark exclude compounded medications from coverage by default unless a specific rider applies.

Patients with employer-sponsored plans in South Dakota may attempt a medical benefit claim rather than a pharmacy claim if the prescribing provider documents a diagnosis of secondary hypogonadism (ICD-10 E23.0 or E29.1) and frames enclomiphene as medically necessary. Success rates for this pathway are low. A prior authorization through the medical benefit requires demonstration that the patient has failed or is not a candidate for an FDA-approved alternative. Because testosterone replacement is FDA-approved and covered, insurers argue that an FDA-approved alternative exists.

Patients who want to pursue insurance coverage should request a Letter of Medical Necessity from their prescribing physician, document serum LH, FSH, and total testosterone lab values showing the secondary pattern (low testosterone with low or inappropriately normal LH/FSH), and specifically note fertility preservation as a treatment goal if applicable. Fertility preservation is a clinical rationale that testosterone replacement cannot satisfy, since exogenous testosterone suppresses spermatogenesis via negative feedback on the hypothalamic-pituitary axis [9].

ACA marketplace plans sold in South Dakota are not required to cover off-label hormone therapies. The essential health benefits (EHB) benchmark for South Dakota does not include a SERM for male hypogonadism.

Telehealth Access to Enclomiphene in South Dakota

Telehealth prescribing of enclomiphene is fully permitted in South Dakota. State law allows licensed physicians and advanced practice providers to prescribe non-controlled medications via synchronous telemedicine after establishing a valid patient-provider relationship, which typically requires a documented medical history, review of laboratory results, and a live video consultation [10].

For enclomiphene specifically, the standard pre-prescription workup includes morning serum total testosterone (two measurements on separate days, drawn before 10 a.m.), LH, FSH, prolactin, estradiol, complete metabolic panel, and a semen analysis if fertility is a concern. A provider who does not order or review lab work before prescribing enclomiphene is practicing below the standard of care.

South Dakota does not require an in-person visit before a telehealth prescriber can issue a non-controlled medication. This is a meaningful access advantage for the roughly 67% of South Dakota's population that lives in rural or frontier counties more than 30 miles from a men's health or endocrinology specialist [6].

Several nationally operating telehealth platforms (HealthRX among them) maintain prescribing relationships with South Dakota patients and route prescriptions to 503A compounders that ship directly to the patient's address within 5, 7 business days. Total time from consultation to medication in hand is typically 7 to 10 days.

The American Urological Association's 2023 male infertility guideline specifically names clomiphene and enclomiphene as options for empiric hormonal therapy in men with secondary hypogonadism and concurrent infertility [11], a recommendation that telehealth providers in South Dakota can apply directly.

Clinical Evidence Supporting Enclomiphene Use

The clinical rationale for enclomiphene rests on several well-conducted trials. Kim et al. (BJU Int, 2016) enrolled 180 men with secondary hypogonadism and compared enclomiphene 12.5 mg and 25 mg daily against testosterone gel 1.62% over 16 weeks [1]. Enclomiphene at 25 mg raised mean morning testosterone from 228 ng/dL to 489 ng/dL (P<0.001) while preserving sperm counts, whereas testosterone gel suppressed sperm concentration by a mean of 25 million/mL [1]. This trial is the most-cited head-to-head comparison and directly informs the clinical decision between testosterone replacement and enclomiphene in reproductive-age men.

A Phase III trial reported in Fertility and Sterility (Wiehle et al., 2014, N=124) showed that enclomiphene 25 mg daily normalized serum testosterone (>300 ng/dL) in 74% of treated men versus 23% on placebo at 12 weeks (P<0.001) [12]. LH rose from a mean of 3.9 mIU/mL to 6.7 mIU/mL, confirming the hypothalamic mechanism of action rather than direct testicular stimulation [12].

A further pharmacokinetic comparison published in the Journal of Clinical Pharmacology demonstrated that the zuclomiphene isomer (cis-clomiphene) reaches a half-life of approximately 30 days due to tissue accumulation, while enclomiphene (trans-clomiphene) clears within 24 to 48 hours [13]. This difference explains why men on long-term clomiphene often develop estrogen-related symptoms that enclomiphene avoids.

The HealthRX clinical team uses the following prescribing decision framework for South Dakota patients requesting enclomiphene vs. testosterone replacement therapy:

Step 1. Confirm secondary hypogonadism pattern: total testosterone <300 ng/dL on two morning draws with LH <7 mIU/mL (inappropriately low or low-normal given the T level).

Step 2. Assess fertility intent. If the patient is actively trying to conceive or wishes to preserve fertility within 24 months, enclomiphene is the first-line choice because it maintains spermatogenesis.

Step 3. Assess estradiol at baseline. If estradiol exceeds 42 pg/mL before treatment, add an aromatase inhibitor discussion to the plan rather than starting enclomiphene alone, because further LH-driven testosterone production will also drive aromatization.

Step 4. Confirm cost tolerance. At $90/month cash-pay with no insurance reimbursement path in South Dakota, a 3-month trial costs roughly $270. Set that expectation at the first visit.

Step 5. Recheck testosterone, LH, FSH, and estradiol at 6 to 8 weeks. Target morning testosterone 450 to 700 ng/dL. Titrate dose between 12.5 mg and 25 mg based on response and symptom burden.

Discount Programs and Ways to Reduce Cost in South Dakota

There are limited but real options for reducing the out-of-pocket cost of compounded enclomiphene in South Dakota.

Telehealth bundled pricing. Several platforms include the cost of the consultation, lab order, and medication in a single monthly subscription. Bundled pricing can bring the effective per-month cost down to $70, $80 when consultation fees are amortized over a 6-month treatment period.

Auto-refill discounts. Most 503A compounders offer 10 to 15% discounts for patients who enroll in automatic monthly shipment. For a $90/month medication, a 10% discount saves $108 annually.

HSA and FSA eligibility. Compounded prescription medications dispensed pursuant to a valid prescription are HSA/FSA-eligible expenses under IRS Publication 502 [14]. South Dakota patients with employer-sponsored health plans that include HSA or FSA accounts can pay for enclomiphene with pre-tax dollars, effectively reducing the after-tax cost by 22 to 32% depending on marginal tax bracket.

GoodRx applicability. GoodRx and similar discount platforms do not apply to compounded medications because compounded drugs lack standard NDC codes. Patients who find a GoodRx coupon for "clomiphene" are seeing a price for the racemic generic, not enclomiphene.

Manufacturer patient assistance. No manufacturer patient assistance program exists for enclomiphene because there is no commercial manufacturer selling an FDA-approved product.

The most actionable cost-reduction step for most South Dakota patients is confirming HSA/FSA eligibility with their benefits administrator and routing payments through that account from the first prescription fill.

Monitoring and Lab Costs in South Dakota

The medication cost is only part of the total treatment expense. A complete baseline lab panel for enclomiphene initiation typically includes total testosterone, LH, FSH, estradiol, prolactin, PSA (for men over 40), CBC, and CMP. At South Dakota cash-pay lab rates through platforms like LabCorp or Quest, this panel runs $80, $150 depending on which tests are ordered individually versus bundled.

Follow-up labs at 6 to 8 weeks (total testosterone, estradiol, LH) cost approximately $40, $80. An annual PSA and metabolic check for ongoing patients adds another $30, $60.

Total first-year cost for a South Dakota man starting enclomiphene via telehealth therefore approximates: $150 telehealth consultation + $120 baseline labs + $1,080 medication (12 months at $90) + $80 follow-up labs = roughly $1,430. This compares favorably with branded testosterone therapies that carry their own access and monitoring costs, particularly testosterone gels with monthly WAC prices of $300, $600 before insurance [15].

The CDC's National Center for Health Statistics reports that hypogonadism-related diagnoses are rising in men under 45, with testosterone testing rates doubling between 2000 and 2018 [16]. That trend makes cost transparency more consequential for patients in states like South Dakota where insurance reimbursement pathways remain closed.